Concordia Hospital
Winnipeg, Manitoba, R2K 3S8, Canada
Location contact
David Hedden, MD FRCSC
SUB_INVESTIGATOR
Sarah Tran
CONTACT
Trevor Gascoyne
CONTACT
NCT Number: NCT06942624
This purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of a bacteriophage therapy in a patient with a methicillin-susceptible Enterococcus faecium (E. faecium) prosthetic joint infection (PJI) of the hip. We have exhausted all surgical and medical management of PJI for our patient.
The phage will be administered to the study patient during a 14 days period via intravenous and intra-articular. The patient will be monitored in clinic for up to 1 year.
Trial opening soon.
Get Notified18 year and older
Male
Interventional
Phase 1 / Phase 2
Winnipeg, Manitoba, R2K 3S8, Canada
David Hedden, MD FRCSC
SUB_INVESTIGATOR
Sarah Tran
CONTACT
Trevor Gascoyne
CONTACT
This is a single-patient study, to assess a treatment option for a case of a recurrent methicillin-susceptible E. faecium infection in a prosthetic hip joint. The patient has repeatedly failed standard of care medical and surgical management.
Given the severity and chronicity of E. faecium infection and burden of infected hardware, the only option to achieve surgical source control would involve an aggressive, high risk surgical approach: a high amputation of the left leg to remove infected hardware and peri-implant bone and tissues. In the absence of any viable adjunctive antimicrobial therapy, this patient is at high risk of mortality and morbidity. It is therefore paramount that we explore alternative treatment modalities for the management of this infection, such as bacteriophage (phage) therapy.
The primary objective of this study is to investigate the preliminary efficacy, safety, and tolerability of systemic (intravenous) and intra-articular administration of a lytic phage (in our patient with chronic E. faecium PJI.
Secondary objectives will be documenting clinical changes pre- and post-therapy, as well as identifying adjunctive changes in biomarkers (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], and interleukin-6 [IL-6]) correlated with PJI as well as phage titres.
In this study, lytic phage prepared in injection-grade saline will be administered to the patient both intravenously and intraarticularly, twice a day for a duration of 14 days. In addition to phage therapy, the patient will receive standard of care antibiotic therapy.
The patient will remain in clinical follow-up for up to one year.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
This N-of-1 Phage therapy is designed for one patient who meet the following conditions
Exclusion criteria
Our phage is an investigational treatment for bacterial infections. Our lytic phage preparation was provided by Cytophage Technologies (CIP-200).
Time frame: Day 0 to 1 year from treatment
Reactions and adverse events to the treatment
Time frame: 1 Year
No recurrence of the infection
Time frame: Day 0 to Day 13 of treatment
Reactions and adverse events to the intravenous and intra-articular administration
Time frame: Day 0 to 1 year from treatment
Serum C-reactive protein (mg/L) as measured at baseline
Time frame: Day 0 to 1 year from treatment
Serum erythrocyte sedimentation rate (mm/hr) as measured at baseline
Time frame: Day 0 to 1 year from treatment
Serum interleukin-6 (pg/mL) as measured at baseline
Time frame: Day 0 to Day 13 of treatment
Phage particles present in a given volume of liquid (PFU/mL)
Contact information is provided by the study sponsor or research team.
Christiaan Righolt, PhD
CONTACT
Sarah Tran
CONTACT
Orthopaedic Innovation Centre
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06189885
Periprosthetic Joint Infection
Kaohsiung City, Taiwan
View Trial DetailsNCT06126614
Periprosthetic Joint Infection
Hamilton, Ontario, Canada
View Trial DetailsNCT06428448
Periprosthetic Joint Infection
Lansing, Michigan, United States
View Trial DetailsNCT07313215
Periprosthetic Joint Infection
Fuzhou, Fujian, China
View Trial Details